ONCT News and Press, Oncternal Therapeutics Inc. From 05/04/23

Phase 1/2 study initiated for ONCT-808, our autologous CAR-T targeting ROR1-expressing hematologic malignancies, with initial clinical data expected in late 2023 Final IND-enabling studies completed for ONCT-534, our novel dual-action androgen receptor inhibitor (DAARI), with expected IND...

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2023 financial results after the U.S. financial markets c...

2023-04-17 11:15:14 ET There were a lot of different micro-trends to watch when it came to penny stocks last week. Whether it was stocks with high short interest, a low float, insider trading activity, or unusual activity, take your pick. We noticed an even more active search for penn...

SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer & ...

2023-04-04 09:10:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nogin (NASDAQ: NOGN ) stock is falling hard on Tuesday after the company revealed details about a public offering for its shares . Nogin is offering 7.33 million shares ...

2023-04-04 08:51:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncternal Therapeutics (NASDAQ: ONCT ) stock is falling hard on Tuesday after the company decided to end two clinical trials . Oncternal Therapeutics has announced that ...

2023-04-03 16:55:43 ET Shares of Oncternal Therapeutics ( NASDAQ: ONCT ) slumped 30.6% to $0.55 in post-market trading on Monday, after the cancer biotech ended two clinical studies in order to extend its cash runway. ONCT shares had been halted for trading at 1600 ET ahea...

Zilovertamab Phase 3 Study ZILO-301 and Phase 1/2 Study CIRM-0001 to be closed based on dynamically changing therapeutic landscape Cash runway extended to 2025, enabling initial clinical data readouts for both ONCT-808, ROR1-tageting CAR T for patients with aggre ssive lymphomas, and ...

SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Onctern...

2023-03-09 21:19:05 ET Oncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Conference Call March 09, 2023, 05:00 PM ET Company Participants James Breitmeyer - President and CEO Richard Vincent - CFO Salim Yazji - Chief Medical Officer Conference Call Parti...